Manufacturing Biosimilars at Scale: Overcoming Complexity, Consistency, and Regulatory Barriers

Biosimilars represent a groundbreaking opportunity to expand patient access to biologic therapies that were once reserved for those who could afford high prices. By definition, a biosimilar is a biologic product that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. The global biosimilar market is projected to exceed $70 billion by 2030, driven by patent expirations of top-selling biologics and increasing healthcare cost pressures. Yet the path from laboratory bench to commercial-scale production is fraught with scientific, engineering, and regulatory obstacles. Successfully manufacturing biosimilars at industrial volumes demands not only deep understanding of the original molecule but also advanced bioprocessing capabilities, robust quality systems, and close coordination with regulators. This article examines the most pressing challenges in scaling biosimilar production and the practical solutions that leading manufacturers are deploying to overcome them.

The Distinctive Challenges of Scaling Biosimilar Production

Structural and Analytical Complexity of Biologics

Unlike small-molecule drugs, biologics are large, intricate proteins with three-dimensional structures that depend on precise folding, post-translational modifications, and aggregation states. Even a minor change in the production process—such as a shift in temperature, pH, or cell culture media—can alter the molecule’s conformation, glycosylation pattern, or impurity profile. For biosimilars, the task is not simply to produce the same amino acid sequence but to achieve near-identical higher-order structure and biological function as the reference product. This requires extensive analytical characterization using orthogonal techniques like mass spectrometry, nuclear magnetic resonance, and advanced chromatography. Defining the critical quality attributes (CQAs) that must be matched is itself a major analytical undertaking.

Glycosylation and Immunogenicity Risk

One of the most complex aspects is replicating the glycosylation profile—the pattern of sugar chains attached to the protein backbone. Differences in glycosylation can affect pharmacokinetics, pharmacodynamics, and immunogenicity. For example, variations in the presence of mannose residues or sialic acid can alter clearance rates or trigger an immune response. Manufacturers must demonstrate that the biosimilar’s glycosylation pattern falls within the range of variability observed for the reference product across multiple batches. Achieving this consistently at commercial scale is a formidable challenge.

Consistency Across Batches and Scale-Up

Maintaining batch-to-batch consistency is more difficult in biologic production than in chemical synthesis because the product is generated by living cells. When scaling up from a 10-liter bioreactor to a 2,000-liter or larger vessel, subtle changes in mixing, oxygen transfer, shear stress, and temperature gradients can cause deviations in cell growth, productivity, and product quality. The inherent variability of biological systems means that even if the process is well-controlled, some drift can occur over time.

Cell Line Stability and Clone Selection

The starting point is the host cell line—typically Chinese hamster ovary (CHO) cells. Selecting a stable, high-producing clone is critical. However, during extended culture in large bioreactors, cells can undergo genetic drift, leading to reduced yield or altered product attributes. Manufacturers must invest in careful clone screening, stability testing, and seed-train management to ensure that the genetic integrity of the production cell line is maintained through successive generations.

Raw Material Variability

Biological production relies on complex growth media containing amino acids, vitamins, growth factors, and other components that themselves are biologically derived. Lot-to-lot variations in raw materials—even from the same supplier—can introduce subtle changes that affect cell metabolism and product quality. Controlling this variability requires rigorous raw material qualification programs, supplier audits, and the use of chemically defined media where possible.

Regulatory and Comparability Hurdles

Regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established specific guidelines for biosimilar approval. These require a comprehensive stepwise demonstration of similarity, starting with extensive physicochemical characterization, followed by functional assays, animal studies, and ultimately clinical pharmacokinetic and pharmacodynamic studies. The regulatory burden is substantial and adds years of development time. Moreover, any process change during commercialization must be carefully managed through a comparability protocol to demonstrate that the product remains highly similar after the change. The fear of a regulatory setback can slow down continuous improvement efforts.

Cost of Facilities and Production Capacity

Building a large-scale biomanufacturing facility requires an investment of hundreds of millions to billions of dollars. The infrastructure must be designed for single-use or stainless-steel operations, with cleanrooms, HVAC systems, water-for-injection loops, and advanced automation. For biosimilar developers that may not have the deep pockets of originator companies, financing such facilities is a major hurdle. Even with sufficient capital, constructing and validating a facility takes three to five years. Market demand projections must be accurate to avoid under- or over-capacity issues.

Practical Solutions for Scaling Biosimilar Manufacturing

Adopting Advanced Bioprocessing Technologies

To address the challenges of consistency and productivity, manufacturers are turning to next-generation bioprocessing tools. Continuous manufacturing, where cells are cultured in a steady-state perfusion mode rather than fed-batch, offers several advantages: it maintains cells in a more consistent environment, reduces hold times, and increases volumetric productivity. Continuous processes also facilitate real-time product removal and purification, which can improve product quality by minimizing degradation.

Process Analytical Technology (PAT)

PAT systems use in-line sensors and probes to monitor key process parameters in real time—such as dissolved oxygen, pH, glucose, lactate, and cell density. By combining PAT with multivariate data analysis and feedback control loops, manufacturers can detect deviations early and adjust conditions to keep the process within the defined design space. This reduces batch failures and supports the concept of quality by design (QbD). For biosimilars, PAT also generates a wealth of data that can be used in regulatory submissions to demonstrate process robustness.

Single-Use Bioreactors and Modular Facilities

Single-use technologies—disposable bags, tubing, and connectors—are now widely adopted because they reduce the risk of cross-contamination, eliminate the need for cleaning validation, and shorten turnaround times between batches. Modular, single-use facilities can be built faster and with lower capital investment than traditional stainless-steel plants. This is particularly attractive for biosimilar companies that need flexibility to switch between products as market dynamics evolve.

Implementing Robust Quality Control and Automation

Consistency is achieved not only by controlling the process but also by scrutinizing the product at every stage. High-throughput analytical methods using mass spectrometry, charge-based separation, and bioassays enable comprehensive characterization of each batch. Automation of sample preparation, data acquisition, and integrated data management systems reduces human error and accelerates decision-making.

Real-Time Release Testing

One emerging goal is real-time release testing (RTRT), where product quality attributes are predicted from in-process measurements and validated models, potentially reducing the need for lengthy end-product testing. For biosimilars, RTRT could shorten the time from batch completion to release, improving supply chain efficiency. However, achieving regulatory acceptance of RTRT requires demonstrating that the models are robust and that the process is well-understood.

Partnering with Regulatory Agencies and Using Innovative Pathways

Early and frequent communication with regulators is a key strategy for de-risking development. Many agencies offer advice through formal scientific meetings or qualification of novel methodologies. For example, the FDA’s Biosimilar Development Program provides consultations on study design and quality expectations. Similarly, the EMA offers parallel scientific advice. By engaging these channels, manufacturers can gain clarity on the extent of data required and avoid costly missteps.

Comparability Protocols and Process Change Management

Once a biosimilar is on the market, process improvements are inevitable. Regulatory guidance allows for the use of comparability protocols (described in ICH Q5E) that outline predefined criteria for evaluating the effect of changes. By preparing such protocols during initial licensing, manufacturers can implement approved changes more quickly after launch, provided they demonstrate that product quality remains comparable. This approach encourages continuous improvement without constant re-approval cycles.

Strategic Investments and Outsourcing

Not every biosimilar developer needs to own its own manufacturing plant. Many choose to partner with contract development and manufacturing organizations (CDMOs) that specialize in biologics. A reputable CDMO can offer access to multiple platforms, experienced teams, and validated facilities without the capital burden. However, transferring a process to a CDMO requires careful technology transfer and oversight to maintain similarity. Some companies adopt a hybrid model: early-stage clinical production in-house and commercial scale-up with a CDMO, or vice versa.

Machine Learning and Digital Twins

Artificial intelligence and machine learning are beginning to play a role in bioprocess development. Predictive models can simulate cell behavior, metabolic fluxes, and product quality under various conditions, reducing the number of lab experiments needed. Digital twins—virtual replicas of the physical bioreactor system—allow manufacturers to test process changes in silico before implementing them in the plant. This can accelerate scale-up and reduce risk.

Subunit Vaccines and Complex Proteins

Beyond monoclonal antibodies, the next wave of biosimilars will target fusion proteins, enzymes, and cytokines. These molecules often present even greater complexities in aggregation and potency. Advances in protein engineering and formulation science will be required to produce them at scale while maintaining stability and shelf life.

Supply Chain Resilience

The COVID-19 pandemic exposed vulnerabilities in the global supply chain for biologics, from raw materials to single-use consumables. Biosimilar manufacturers are now diversifying suppliers, increasing inventory buffers, and considering regional production hubs to mitigate disruptions. Regulatory incentives for supply chain resilience may further shape manufacturing strategies.

Conclusion

Scaling biosimilar manufacturing from laboratory development to reliable commercial production is an arduous journey that requires solving deep scientific and operational puzzles. The complexity of biological molecules, the need for unwavering consistency across thousands of liters of culture, and the rigor of global regulatory pathways combine to create a challenging environment. Yet the industry has demonstrated that these obstacles are not insurmountable. Through the adoption of advanced bioprocessing technologies like continuous manufacturing and PAT, the implementation of robust quality systems, and proactive engagement with regulators, manufacturers are steadily improving both the efficiency and reliability of biosimilar production. As the market continues to grow and newer, even more complex biologics become candidates for biosimilar development, the investments made today in scalable, well-controlled processes will pay dividends in the form of affordable, life-saving treatments for patients around the world.

External Links: